Quickfire Q&A delivers in-person insights from congresses, bringing together expert perspectives on the studies and data shaping clinical practice.
In this episode, recorded at the European Hematology Association (EHA) 2026 Congress, we speak to Cecilia Karlström, Karolinska Institute, Stockholm, Sweden, about the latest developments in immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), including new data on rilzabrutinib, emerging immunological therapies, and the move towards more personalised disease management.
Key topics discussed include:
- The LUNA3 study: Rapid, durable responses and reduced fatigue with rilzabrutinib.
- Emerging therapies: The potential of new targeted approaches in ITP.
- TTP management: The importance of early and intensive treatment.
- Personalised care: The role of closer monitoring and earlier intervention.
- Future treatment: Why individualised and combination approaches matter.
Disclosure: Karlström has declared receiving honoraria from Amgen; and participating in data safety monitoring or advisory boards for Takeda, Sanofi, and Grifols.
Read the latest issue of EMJ Hematology, published on 23rd July, for more expert insights and highlights from EHA 2026.
